The tamoxifen market was worth USD 676.6 Million in 2017, and is predicted to grow to USD 687.44 Million by 2032, with a CAGR of 0.07%.
| Attributes | Details |
|---|---|
| Tamoxifen Market (CAGR) | 0.07% |
| Tamoxifen Market (2032) | USD 687.44 Million |
Tamoxifen is a selective estrogen receptor modulator that decreases the risk of invasive breast cancer and is used to treat estrogen receptor-positive breast cancer. It is the therapy of choice for premenopausal women. Retroperitoneal fibrosis, gynecomastia, infertility, and idiopathic sclerosing mesenteritis are all treated with tamoxifen off-label.
The emergence of combination therapies and additional therapeutic indications for tamoxifen will expand the demand for tamoxifen, as will rising cancer prevalence, rising healthcare expenditure, development of treatment options, rising government funding, rising initiatives by government and private organizations to spread awareness about breast cancer, and rising initiatives by government and private organizations to spread awareness about breast cancer.
The tamoxifen market will benefit from increased research and development efforts as well as growing economies.
However, the high cost of medication and side effects associated with tamoxifen, such as menstrual changes, hot flashes, nausea, vaginal discharge, weight loss, blurred vision, new breast lump, high calcium levels in the blood, and liver problems, will inhibit tamoxifen market growth and pose a new challenge to the sales of tamoxifen during the forecast period.
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The widespread demand for tamoxifen as adjuvant therapy, as well as the proven long-term efficacy of hormone therapy for management and control of breast cancer across various stages of treatment, in geriatric patients who cannot opt for surgery and late-stage and recurrent breast cancer, are the primary factors driving demand for tamoxifen and sales of tamoxifen.
The rise of tamoxifen-resistant malignancy and increased knowledge of the drug's role in causing endometrial cancer may limit the expansion of demand for tamoxifen and sales of tamoxifen.
The growing demand for tamoxifen and sales of tamoxifen in the treatment of illnesses such McCune-Albright syndrome, infertility, gynecomastia, bipolar disorder, angiogenesis, and Riedel's thyroiditis, as well as its usage in gene expression research investigations, provide potential growth opportunities for tamoxifen market share.
The tamoxifen market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa (MEA). North American region is further bifurcated into countries such as U.S. and Canada. The Europe region is further categorized into the U.K., France, Germany, Italy, Spain, Russia, and the Rest of Europe.
The Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and the Rest of Asia Pacific for the tamoxifen market.
Latin America region is further segmented into Brazil, Mexico, and the Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and the Rest of MEA for the tamoxifen market share.
The sales of tamoxifen for tamoxifen medications are seen in North America.
Due to the presence of major key players in the tamoxifen market, rising breast cancer prevalence increased awareness of breast cancer screening and prevention, high healthcare spending, and a well-developed healthcare system in this area. North America dominates the demand for tamoxifen.
Due to increased research and development activities, rising healthcare expenditure, and expanding government backing, Asia-Pacific is predicted to rise over the forecast period in addition to the increased sales of tamoxifen.
The primary drivers for the demand for tamoxifen in the Rest of the World market include increasing awareness in the Middle East and Africa, a high prevalence of late-stage breast cancer in these countries, and fast expansion of healthcare infrastructure in these regions, along with high demand for tamoxifen and sales of tamoxifen.
Principal Consultant
Allergan, AstraZeneca, Mylan N.V., Teva Pharmaceutical Industries Ltd., Apotex Inc., Midatech Pharma PLC, Bayer AG, Sanofi, Cipla Inc., WOCKHARDT, Pfizer Inc., Actiza Pharmaceutical Private Limited, Fuan Pharmaceutical (Group) Co., Ltd., and YZJ Group, among other domestic and global players, are among the major players covered in the tamoxifen market report. North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA), and South America tamoxifen market share statistics are all accessible individually.
The anticipated merger of Teva with Allergan is expected to bring a shift in market competition and demand for tamoxifen.
Future Market Insights analysts are familiar with competitive advantages and give competitive analysis for each rival individually in the tamoxifen market share.
| Report Attribute | Details |
|---|---|
| Growth rate | CAGR of 0.07% from 2022 to 2032 |
| Base year for estimation | 2021 |
| Historical data | 2015 to 2020 |
| Forecast period | 2022 to 2032 |
| Quantitative units | Revenue in USD billion, volume in kilotons, and CAGR from 2022 to 2032 |
| Report coverage | Revenue forecast, volume forecast, company ranking, competitive landscape, growth factors, and trends, Pricing Analysis, |
| Segments covered | Type, Application, Distribution Channel, Route of Administration, End User, Region |
| Regional scope | North America; Western Europe; Eastern Europe; Middle East; Africa; ASEAN; South Asia; Rest of Asia; Australia and New Zealand |
| Country scope | USA, Canada, Mexico, Germany, UK, France, Italy, Spain, Russia, Belgium, Poland, Czech Republic, China, India, Japan, Australia, Brazil, Argentina, Colombia, Saudi Arabia, UAE, Iran, South Africa |
| Key companies profiled | Allergan; AstraZeneca; Mylan N.V.; Teva Pharmaceutical Industries Ltd.; Apotex Inc.; Midatech Pharma PLC; Bayer AG; Sanofi, Cipla Inc.; WOCKHARDT; Pfizer Inc.; Actiza Pharmaceutical Private Limited; Fuan Pharmaceutical (Group) Co.,Ltd.; and YZJ Group |
| Customization scope | Free report customization (equivalent to up to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope. |
| Pricing and purchase options | Avail customized purchase options to meet your exact research needs. |
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The tamoxifen market is segmented into two types--tablets and capsules.
The tamoxifen market is segmented on basis of application into Breast Cancer, Ovarian Cancer, and Other.
Based on region, the tamoxifen market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA).
The tamoxifen market is segmented on the basis of end users, into clinic, hospital and others.
The tamoxifen market is segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Dosage Form 6.2. Indication 7. Global Market Analysis and Forecast, By Dosage Form 7.1. Powder 7.2. Capsule 7.3. Oral Solution 7.4. Tablet 8. Global Market Analysis and Forecast, By Indication 8.1. Breast Cancer 8.2. Others 9. Global Market Analysis and Forecast, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. Asia Pacific 9.6. Japan 9.7. Middle East and Africa 10. North America Sales Analysis and Forecast, by Key Segments and Countries 11. Latin America Sales Analysis and Forecast, by Key Segments and Countries 12. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 13. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 15. Japan Sales Analysis and Forecast, by Key Segments and Countries 16. Middle East and Africa Sales Analysis and Forecast, by Key Segments and Countries 17. Sales Forecast by Dosage Form and Indication for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. AstraZeneca plc 19.2. Pfizer Inc. 19.3. Mylan N.V. 19.4. Teva Pharmaceutical Industries Ltd. 19.5. Novartis International AG 19.6. Sun Pharmaceutical Industries Ltd. 19.7. Dr. Reddy's Laboratories Ltd. 19.8. Cipla Limited 19.9. Accord Healthcare Inc. 19.10. Apotex Inc.
Explore Healthcare Insights
View Reports
Tamoxifen Market
